Post trial results, AstraZeneca CEO says smaller first dose in COVID-19 vaccine is 'big plus'
The British drugmaker said on Monday its vaccine for the novel coronavirus could be around 90% effective without any serious side effects.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: AstraZeneca | Biotechnology | Coronavirus | COVID-19 | Pharmaceuticals | UK Health | Vaccines